

## Press Release

### Initiatives to Pursue Operational Excellence

Tokyo, November 30, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) is promoting its strategic goal “Pursuing Operational Excellence” and engaged in ongoing efforts to create organizations and systems that can flexibly respond to rapidly changing environments and realize higher quality and efficiency of operations. As one of these initiatives, Astellas will promote outsourcing of a part of the shared administrative support works for Astellas and its subsidiaries in Japan. Through collaboration with external partners with specialized capabilities, Astellas aims to receive high quality services and promote efficiency while allocating its resources to businesses that contribute to the competitive advantage.

Astellas executed a memorandum of understanding for outsourcing of the facility and equipment management support of such shared administrative support works with Kajima Corporation (TSE: 1812, President and Representative Director: Yoshikazu Oshimi) and Kajima Tatemono Sogo Kanri Co., Ltd. (President and Representative Director: Masao Taku, collectively with Kajima Corporation “Kajima Group”).

In addition to the outsourcing, as a result of re-assessment of the organizational operation structure, Astellas decided that its subsidiary, Astellas Business Service Company Limited (“ABS”) which performs the shared administrative support works would be dissolved as of the end of September 2017. A part of ABS’ employees are planned to work at Kajima Tatemono Sogo Kanri Co., Ltd., or transfer to Astellas or its subsidiaries in Japan. An early retirement incentive program will be also offered to employees working at ABS in the fiscal year 2017.

The impact of the outsourcing to Kajima Group, the dissolution of ABS and the early retirement incentive program on the financial results for the fiscal year ending March 31, 2017 is minor.

###

#### About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare

business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

#### **Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

---

#### **Contacts for inquiries or additional information:**

Astellas Pharma Inc.  
Corporate Communications  
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473